Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.
about
Cell Therapy in Patients with Critical Limb IschemiaTargeting the molecular and cellular interactions of the bone marrow niche in immunologic diseaseRegulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.Medical management of radiation injuries: current approachesStroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesisAMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agentClinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migrationMLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonismCXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development.Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production.Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial.Peripheral blood stem cell mobilization: new regimens, new cells, where do we standThe hematopoietic stem cell niche.Chemokine-mobilized adult stem cells; defining a better hematopoietic graft.Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model.Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cellsStromal reengineering to treat pancreas cancerPersistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer.Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease.CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarctionAn effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells.Global transcriptional analysis for biomarker discovery and validation in cellular therapies.Turning CD34 Non-Mobilizers into Mobilizers: A Case Report Involving Plerixafor (AMD3100).Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblastsQuality assessment of cellular therapies: the emerging role of molecular assays.Pharmacological mobilization of endogenous stem cells significantly promotes skin regeneration after full-thickness excision: the synergistic activity of AMD3100 and tacrolimus.Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonistImpact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors.CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation.SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gαi/mTORC1 axis.CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal ratsCXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in mice.Hematopoietic stem cells: transcriptional regulation, ex vivo expansion and clinical application.Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor.AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.Challenges for heart disease stem cell therapy.
P2860
Q26795443-D8582D13-F5B4-49E5-9739-3F5F0BAC164AQ26865498-7F61A8D7-5381-43A2-A536-143BE76D0E7DQ27692619-D41DB446-3E80-40D2-B017-B52B253E127EQ28236743-F9CBEC38-BCE7-4A5C-813A-36E16016ADB8Q28260997-F0BAD9B2-478C-4FE0-9B7E-83BE970919F3Q28286940-F5E7FD11-22D9-4754-93DF-D2140E038A7AQ28302968-8FB00637-CCCA-428E-A373-80BE47FE29F6Q28658170-B796CC4C-6BA1-4644-B8EF-9AF73BAC90B2Q30487339-220F482D-B7D4-49C2-AD76-91A8E478C121Q33369569-379EE0B4-DA5E-4B7F-9C12-B53624A13825Q33409463-492F54EC-4618-46E6-BF29-09D07B084587Q33573756-42A86D85-CA4C-4C0F-B236-122DC9E6684CQ33589591-3C7EF493-1062-4452-B85A-325A0A390379Q33607827-31EB02EE-F658-4C17-AED0-56E0F56D31ACQ33623545-0A717359-1E27-425C-A599-D1A2FCBA1308Q33623571-801B4F05-FB26-45E9-B383-48695239CAE6Q33731221-11B53C01-B125-45E2-ABC8-A0FCB4CAB20BQ33827708-F4C6E205-AA6F-41BB-B78A-4FFC7EBE7658Q33868710-18A5B80B-D811-4AF8-A287-FF3FFECA47F3Q33925035-2C976579-78CF-4150-904C-B69F2F3A322FQ33934547-6AE3509F-B1BB-45A6-B0A8-0B43DDD2805DQ34016950-303C0292-340A-4757-9BC9-8C1A860B080CQ34105074-C7BD1A9F-5AE6-44E6-9C32-C2F0CDBAF0B3Q34171422-ABE030C9-D162-4841-80D9-466321ADDC7AQ34263566-933164A8-9720-4BB3-80DD-C17C3FAC64D3Q34280104-6836F2EC-4A5B-443B-9344-80B2EEF8D36DQ34316777-E07C7196-654D-467D-BAAA-1FD8CD4E0685Q34328240-99DD9973-AE60-4A86-A903-B6283E286B3BQ34412254-9A87193D-FBC1-41F0-B04E-9929AE05CD47Q34451574-D9E18A37-4C79-4563-9336-EDA60F8A732CQ34476278-5AC5A5D4-2E1F-40E7-A981-0937284169C7Q34654670-5D8CCDF9-5165-471D-8CCB-9D2A4CC985BEQ35080100-7EB15B92-0117-42A9-9B9E-2FDF9168D209Q35576488-45162F09-2B4C-4E23-85A3-695B33D24508Q35690521-D09212D2-0ADC-4CD9-BCCE-143ADD935201Q35706089-F99F6137-0716-4FFA-824E-6F6630FBDB2AQ35777496-C9DCF2DE-0C61-466E-8CE0-33A8C1221E3EQ35793034-AC22E0E3-9B92-40F7-97D9-295495F1A6A2Q35794312-D3C2D178-AE38-4464-BE17-2AD1055AB3E9Q35808738-E2006F14-DC61-4E7A-9A03-9B688CDEF7EF
P2860
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Rapid mobilization of CD34+ ce ...... ma and non-Hodgkin's lymphoma.
@en
Rapid mobilization of CD34+ ce ...... ma and non-Hodgkin's lymphoma.
@nl
type
label
Rapid mobilization of CD34+ ce ...... ma and non-Hodgkin's lymphoma.
@en
Rapid mobilization of CD34+ ce ...... ma and non-Hodgkin's lymphoma.
@nl
prefLabel
Rapid mobilization of CD34+ ce ...... ma and non-Hodgkin's lymphoma.
@en
Rapid mobilization of CD34+ ce ...... ma and non-Hodgkin's lymphoma.
@nl
P2093
P356
P1476
Rapid mobilization of CD34+ ce ...... ma and non-Hodgkin's lymphoma.
@en
P2093
Daniel Weisdorf
David H Vesole
Gary Calandra
Jane Liesveld
John F DiPersio
Karin Badel
Neal Flomenberg
Steven M Devine
P304
P356
10.1200/JCO.2004.07.131
P407
P577
2004-03-01T00:00:00Z